Stepanishyna Y, Skrypets T, Novosad O, Pastushenko I, Kryacohk I.
#Ritxumiab radiation unfolder trial plus
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Recher C, Coiffier B, Haioun C, et al Groupe d’Etude des Lymphomes de l’Adulte. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. R-CHOP in primary mediastinal B-cell lymphoma (PMBL): results from the UK NCRI R-CHOP 14 v 21 Trial. Gleeson M, Hawkes EA, Cunningham D, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. Dunleavy K, Pittaluga S, Maeda LS, et al. Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy. Massoud M, Koscielny S, Lapusan S, Bosq J, Ribrag V. Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Swerdlow SH, Campo E, Pileri SA, et al. Our data confirmed the prognostic importance of baseline TMTV. R-ACVBP acute toxicity was higher than that of R-CHOP14. Patients with PMBL treated with dose-dense immunochemotherapy without radiotherapy have excellent outcomes. 001) were observed with R-ACVBP compared with the R-CHOP regimens. Excess febrile neutropenia (24.4% vs 5.3% vs 5.3% P <. A baseline total metabolic tumor volume (TMTV) ≥360 cm3 was associated with a lower progression-free survival (hazard ratio, 2.18 95% CI, 1.05-4.53). 23) in the R-ACVBP, R-CHOP14, and R-CHOP21 groups. The end-of-treatment complete metabolic response rates were 86.3%, 86.8%, and 76.6% (P =. 001) only 17 (5.4%) patients received mediastinal radiotherapy. 
Consolidation autologous stem cell transplantation was performed for 46 (25.6%), 24 (31.6%), and 1 (1.8%) patient in the R-ACVBP, R-CHOP14, and R-CHOP21 groups, respectively (P <. A total of 313 patients were enrolled and received rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) (n = 180) or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) delivered every 14 days (R-CHOP14, n = 76) or 21 days (R-CHOP21, n = 57) and consolidation strategies in modalities that varied according to time and institution, mainly guided by positron emission tomography. We performed a large multicenter retrospective study in 25 centers in France and Belgium to describe PMBL patient outcomes after first-line treatment in real-life settings. The first-line standard of care remains debated. Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive lymphoma typically affecting young female patients.
0 kommentar(er)
